Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November

NEWTON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will present a corporate update at two investor conferences in November:

Credit Suisse 27^th Annual Healthcare Conference
Date: Tuesday, November 13, 2018
Time: 9:10 a.m. MT (11:10 a.m. ET)
Location: Scottsdale, AZ

Evercore ISI HealthconX
Date: Tuesday, November 27, 2018
Time: 4:35 p.m. ET
Location: Boston, MA

Live audio webcasts of both presentations will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]

You May Also Be Interested In

• CleanSpark, Inc. Announces Closing of $2.276 Billion of Senior Secured Notes
• Best Crypto to Buy Before Altcoin Season: HBAR or Remittix at $0.21 Before Its $0.46 Final Stage as Bulls Eye $3.50?
• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)